Pfizer and BioNTech say a three-shot course of their COVID-19 vaccine was able to neutralize the new omicron variant in a laboratory test, and that they could deliver an omicron-based vaccine in March 2022 if needed.
In the first official statement from vaccine manufacturers on the likely efficacy of their shot against the latest variant of concern, the companies said on Wednesday that two vaccine doses resulted in significantly lower neutralizing antibodies, but that a third dose of their vaccine increased the neutralizing antibodies by a factor of 25.
Blood obtained from people that had their third booster shot a month ago neutralized
This story was originally published on CBC News. To read the rest of this news worthy story, please visit https://www.cbc.ca/news/health/pfizer-omicron-vaccine-1.6277600?cmp=rss.
